Notice for ipilimumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
ipilimumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Yervoy in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma
Therapeutic area
Oncology